The impact of 5-formyltetrahydrofolate on the anti-tumor activity of pralatrexate, as compared to methotrexate, in HeLa cells in vitro

Cancer Chemotherapy and Pharmacology

Volumn 73, Issue 5, 2014, Pages 1055-1062

  Visentin, Michele ^a   Unal, Ersin Selcuk ^a   Goldman, I David ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

(6S)5 formyltetrahydrofolate; 5 Formyltetrahydrofolate; Folylpolyglutamate synthetase; Leucovorin; Methotrexate; Pralatrexate; Reduced folate carrier; Rescue

Indexed keywords

FOLINIC ACID; METHOTREXATE; PRALATREXATE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG EFFECT; DRUG EXPOSURE; DRUG SCREENING; GROWTH INHIBITION; HELA CELL LINE; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; INCUBATION TIME; PRIORITY JOURNAL;

AMINOPTERIN; CARBON-NITROGEN LIGASES; FOLIC ACID ANTAGONISTS; HELA CELLS; HUMANS; METHOTREXATE; NEOPLASMS; TUMOR CELLS, CULTURED;

EID: 84900792195     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-014-2441-9     Document Type: Article

References (35)

1. Sirotnak FM, DeGraw JI, Colwell WT, Piper JR (1998) A new analogue of 10-deazaaminopterin with markedly enhanced curative effects against human tumor xenografts in mice. Cancer Chemother Pharmacol 42:313-318 (Pubitemid 28393849)
2. Goldman ID, Chattopadhyay S, Zhao R, Moran RG (2010) The Antifolates: evolution, new agents in the clinic, and how targeting delivery via specific membrane transporters is driving the development of a next generation of folate analogs. Curr Opin Investig Drugs 11:1409-1423
3. Visentin M, Zhao R, Goldman ID (2012) The antifolates. Hematol Oncol Clin N Am 26:629-648
4. Visentin M, Unal ES, Zhao R, Goldman ID (2013) The membrane transport and polyglutamation of pralatrexate: a new-generation dihydrofolate reductase inhibitor. Cancer Chemother Pharmacol 72:597-606
5. O'Connor OA, Horwitz S, Hamlin P, Portlock C, Moskowitz CH, Sarasohn D, Neylon E, Mastrella J, Hamelers R, Macgregor-Cortelli B, Patterson M, Seshan VE, Sirotnak F, Fleisher M, Mould DR, Saunders M, Zelenetz AD (2009) Phase II-I-II study of two different doses and schedules of pralatrexate, a high-affinity substrate for the reduced folate carrier, in patients with relapsed or refractory lymphoma reveals marked activity in T-cell malignancies. J Clin Oncol 27:4357-4364
6. O'Connor OA, Pro B, Pinter-Brown L, Bartlett N, Popplewell L, Coiffier B, Lechowicz MJ, Savage KJ, Shustov AR, Gisselbrecht C, Jacobsen E, Zinzani PL, Furman R, Goy A, Haioun C, Crump M, Zain JM, Hsi E, Boyd A, Horwitz S (2011) Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study. J Clin Oncol 29:1182-1189
7. Foss F, Horwitz SM, Coiffier B, Bartlett N, Popplewell L, Pro B, Pinter-Brown LC, Shustov A, Furman R, Haioun C, Koutsoukos T, O'Connor OA (2012) Pralatrexate is an effective treatment for relapsed or refractory transformed mycosis fungoides: a subgroup efficacy analysis from the PROPEL study. Clin Lymphoma Myeloma Leuk 12:238-243
8. Weems G (2013) Study of pralatrexate in female patients with previously-treated breast cancer. http://www.clinicaltrials.gov/ct2/show/ NCT01118624?term=pralatrexate&rank=16. Accessed 23 Nov 2013
9. Weems G (2013) Study of pralatrexate vs. erlotinib for non-small cell lung cancer after at least 1 prior platinum-based treatment. http://www.clinicaltrials.gov/ct2/show/NCT00606502?term=pralatrexate&rank=1. Accessed 21 Nov 2013
10. Malik SM, Liu K, Qiang X, Sridhara R, Tang S, McGuinn WD Jr, Verbois SL, Marathe A, Williams GM, Bullock J, Tornoe C, Lin SC, Ocheltree T, Vialpando M, Kacuba A, Justice R, Pazdur R (2010) Folotyn (pralatrexate injection) for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma: U.S. Food and Drug Administration drug approval summary. Clin Cancer Res 16:4921-4927
11. Sawas A (2013) Phase 1 Study of fusilev to prevent or reduce mucositis in patients with non-hodgkin's lymphoma receiving folotyn. http://www. clinicaltrials.gov/ct2/show/NCT01789723?term=pralatrexate&rank=10. Accessed 23 Nov 2013
12. Koch E, Story SK, Geskin LJ (2013) Preemptive leucovorin administration minimizes pralatrexate toxicity without sacrificing efficacy. Leuk Lymphoma 54:2448-2451
13. Zhao R, Babani S, Gao F, Liu L, Goldman ID (2000) The mechanism of transport of the multitargeted antifolate, MTA-LY231514, and its cross resistance pattern in cell with impaired transport of methotrexate. Clin Cancer Res 6:3687-3695
14. Zhao R, Gao F, Goldman ID (2001) Marked suppression of the activity of some, but not all, antifolate compounds by augmentation of folate cofactor pools within tumor cells. Biochem Pharmacol 61:857-865 (Pubitemid 32245569)
15. Chattopadhyay S, Tamari R, Min SH, Zhao R, Tsai E, Goldman DI (2007) Commentary: a case for minimizing folate supplementation in clinical regimens with pemetrexed based on the marked sensitivity of the drug to folate availability. Oncologist 12:808-815 (Pubitemid 47328224)
16. Desmoulin SK, Wang L, Polin L, White K, Kushner J, Stout M, Hou Z, Cherian C, Gangjee A, Matherly LH (2012) Functional loss of the reduced folate carrier enhances the antitumor activities of novel antifolates with selective uptake by the proton-coupled folate transporter. Mol Pharmacol 82:591-600
17. McCloskey DE, McGuire JJ, Russell CA, Rowan BG, Bertino JR, Pizzorno G, Mini E (1991) Decreased folylpolyglutamate synthetase activity as a mechanism of methotrexate resistance in CCRF-CEM human leukemia sublines. J Biol Chem 266:6181-6187 (Pubitemid 21906201)
18. Zhao R, Titus S, Gao F, Moran RG, Goldman ID (2000) Molecular analysis of murine leukemia cell lines resistant to 5,10-ideazatetrahydrofolate identifies several amino acids critical to the function of folylpolyglutamate synthetase. J Biol Chem 275:26599-26606
19. Sirotnak FM, Chello PL, Moccio DM, Kisliuk RL, Combepine G, Gaumont Y, Montgomery JA (1979) Stereospecificity at carbon 6 of formyltetrahydrofolate as a competitive inhibitor of transport and cytotoxicity of methotrexate in vitro. Biochem Pharmacol 28:2993-2997 (Pubitemid 10236211)
20. Straw JA, Szapary D, Wynn WT (1984) Pharmacokinetics of the diastereoisomers of leucovorin after intravenous and oral administration to normal subjects. Cancer Res 44:3114-3119 (Pubitemid 14081451)
21. Priest DG, Schmitz JC, Bunni MA, Stuart RK (1991) Pharmacokinetics of leucovorin metabolites in human plasma as a function of dose administered orally and intravenously. J Natl Cancer Inst 83:1806-1812
22. Zhao R, Goldman ID (2003) Resistance to antifolates. Oncogene 22:7431-7457 (Pubitemid 37487168)
23. Allegra CJ, Chabner BA, Drake JC, Lutz R, Rodbard D, Jolivet J (1985) Enhanced inhibition of thymidylate synthase by methotrexate polyglutamates. J Biol Chem 260:9720-9726 (Pubitemid 15013030)
24. Allegra CJ, Hoang K, Yeh GC, Drake JC, Baram J (1987) Evidence for direct inhibition of de novo purine synthesis in human MCF-7 breast cells as a principal mode of metabolic inhibition by methotrexate. J Biol Chem 262:13520-13526 (Pubitemid 17144303)
25. Allegra CJ, Drake JC, Jolivet J, Chabner BA (1985) Inhibition of folate-dependent enzymes by methotrexate polyglutamates. 348-359
26. Matherly LH, Barlowe CK, Phillips VM, Goldman ID (1987) The effects of 4-aminoantifolates on 5-formyltetrahydrofolate metabolism in L1210 cells. J Biol Chem 262:710-717
27. Fry DW, Anderson LA, Borst M, Goldman ID (1983) Analysis of the role of membrane transport and polyglutamylation of methotrexate in gut and Ehrlich tumor in vivo as factors in drug sensitivity and selectivity. Cancer Res 43:1087-1092 (Pubitemid 13160027)
28. Fabre I, Fabre G, Goldman ID (1984) Polyglutamylation, an important element in methotrexate cytotoxicity and selectivity in tumor versus murine granulocytic progenitor cells in vitro. Cancer Res 44:3190-3195 (Pubitemid 14098554)
29. Poser RG, Sirotnak FM, Chello PL (1981) Differential synthesis of methotrexate polyglutamates in normal proliferative and neoplastic mouse tissues in vivo. Cancer Res 41:4441-4446 (Pubitemid 12201355)
30. Koizumi S, Curt GA, Fine RL, Griffin JD, Chabner BA (1985) Formation of methotrexate polyglutamates in purified myeloid precursor cells from normal human bone marrow. J Clin Invest 75:1008-1014 (Pubitemid 15115270)
31. Matherly LH, Fry DW, Goldman ID (1983) Role of methotrexate polyglutamylation and cellular energy metabolism in inhibition of methotrexate binding to dihydrofolate reductase by 5-formyltetrahydrofolate in Ehrlich tumor cells in vitro. Cancer Res 43:2694-2699 (Pubitemid 13100534)
32. Matherly LH, Barlowe CK, Goldman ID (1986) Antifolate polyglutamylation and competitive drug displacement at dihydrofolate reductase as important elements in leucovorin rescue in L1210 cells. Cancer Res 46:588-593 (Pubitemid 16145406)
33. Goldin A, Mantel N, Greenhouse SW, Venditti JM, Humphreys SR (1953) Estimation of the antileukemic potency of the antimetabolite aminopterin, administered alone and in combination with citrovorum factor or folic acid. Cancer Res 13:843-850
34. Goldin A, Venditti J, Kline I, Mantel N (1966) Eradication of leukaemic cells (l1210) by methotrexate and methotrexate plus citrovorum factor. Nature 212:1548-1550
35. Browman GP, Goodyear MD, Levine MN, Russell R, Archibald SD, Young JE (1990) Modulation of the antitumor effect of methotrexate by low-dose leucovorin in squamous cell head and neck cancer: a randomized placebo-controlled clinical trial. J Clin Oncol 8:203-208 (Pubitemid 20056549)